AI Verdict
IBOC has stronger fundamentals based on our AI analysis.
IBRX vs IBOC Fundamental Comparison
| Metric | IBRX | IBOC |
|---|---|---|
| Revenue | $113.3M | $886.3M |
| Net Income | $-351.4M | $412.3M |
| Net Margin | -310.2% | 46.5% |
| ROE | N/A | 12.7% |
| ROA | -70.0% | 2.5% |
| Current Ratio | 5.10x | N/A |
| Debt/Equity | N/A | 0.00x |
| EPS | $-0.38 | $6.62 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
IBRX vs IBOC: Frequently Asked Questions
Is IBRX or IBOC a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), IBOC has stronger fundamentals. IBRX is rated STRONG SELL (92% confidence) while IBOC is rated HOLD (67% confidence). This is not investment advice.
How does IBRX compare to IBOC fundamentally?
ImmunityBio, Inc. has ROE of N/A vs INTERNATIONAL BANCSHARES CORP's 12.7%. Net margins are -310.2% vs 46.5% respectively.
Which stock pays higher dividends, IBRX or IBOC?
IBRX has a dividend yield of N/A or no dividend while IBOC has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in IBRX or IBOC for long term?
For long-term investing, consider that IBRX has STRONG SELL rating with 92% confidence, while IBOC has HOLD rating with 67% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about IBRX vs IBOC?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For IBRX vs IBOC, the AI consensus favors IBOC based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.